Otsuka Pakistan Limited (PSX:OTSU)

Market Cap	2.30B
Revenue (ttm)	3.37B
Net Income (ttm)	4.10M
Shares Out	12.10M
EPS (ttm)	0.34
PE Ratio	561.57
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,023
Average Volume	14,622
Open	205.80
Previous Close	199.17
Day's Range	198.18 - 205.80
52-Week Range	105.05 - 235.98
Beta	0.32
RSI	47.35
Earnings Date	Feb 17, 2025

About Otsuka Pakistan

Otsuka Pakistan Limited manufactures, markets, and distributes intravenous infusions in Pakistan and Afghanistan. The company offers intravenous solutions, including electrolyte and standard solutions, ampoules, OTSUZOL, and ciprofloxacin and OTSUMOL infusion products; medical devices, such as urea breath test systems, plasline solutions, sirolimus eluting coronary stent system, eucaLIMUS, and eucaVI; clinical nutrition products comprising aminoleban oral, aminovel 600, pan-amin G, aminoleban injection, and proten gold; and therapeutic drugs, w...

• Industry: Pharmaceuticals
• Sector: Healthcare
• Founded: 1988
• Employees: 345
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: OTSU

Financial Performance

In 2024, Otsuka Pakistan's revenue was 3.16 billion, an increase of 4.24% compared to the previous year's 3.04 billion. Losses were -4.76 million, -33.91% less than in 2023.